Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Actavis Generics
Allergan's generics business |
| gptkbp:CEO |
Kåre Schultz
|
| gptkbp:employees |
approximately 7,000
|
| gptkbp:focus |
research and development
quality assurance clinical trials corporate social responsibility metabolic disorders neurology oncology pediatrics supply chain management sustainability initiatives autoimmune diseases market access orthopedics psychiatry vaccines dermatology multiple sclerosis biologics hormonal therapies infectious diseases pain management anesthesia pharmacovigilance women's health ophthalmology patient support programs biosimilars urology gastroenterology regulatory affairs cardiovascular respiratory OTC products healthcare_professional_education |
| gptkbp:founded |
1901
|
| gptkbp:headquarters |
gptkb:North_Wales,_Pennsylvania
|
| https://www.w3.org/2000/01/rdf-schema#label |
Teva USA
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:market |
gptkb:United_States
|
| gptkbp:parentCompany |
gptkb:Teva_Pharmaceutical_Industries
|
| gptkbp:products |
generic drugs
specialty medicines |
| gptkbp:revenue |
$18.9 billion (2020)
|
| gptkbp:subsidiary |
Teva Pharmaceuticals USA, Inc.
|
| gptkbp:website |
www.tevapharm.com
|